Nurse-Led Walk-and-Eat Intervention May Improve Outcomes for Patients With Esophageal Cancer
the ONA take:
A nurse-led walk-and-eat intervention is feasible and effective to preserve functional walking capacity and nutritional status in patients with esophageal cancer undergoing neoadjuvant chemoradiotherapy, according to a recent study published in the journal The Oncologist.
For the study, researchers at National Taiwan University in Taipei, Taiwan, sought to evaluate the impact of a walk-and-eat intervention in patients with locally advanced esophageal cancer stage 2B or higher receiving neoadjuvant chemotherapy and radiation. A total of 59 participants were randomly assigned to receive the intervention, which involved nurse-supervised walking 3 times per week and weekly nutritional advice, or usual care during 4 to 5 weeks of chemoradiotherapy.
Results showed that those who received the intervention had a 100-meter less decline in walk distance than control patients, 3-kg less decrease in hand-grip strength, and 2.7-kg less reduction in body weight. Researchers found that the patients’ age did not impact these endpoints.
The study also demonstrated that patients that received the walk-and-eat intervention had significantly lower rates of need for intravenous nutritional support and wheelchair use.
“Nurses can implement this intervention in radiation oncology departments, provided physician and nursing leadership cooperate to achieve compliance with the protocols,” the authors suggest.
A Walk-and-Eat Intervention Improves Outcomes for Patients With Esophageal Cancer Undergoing Neoadju
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|